Literature DB >> 28192563

Evaluation of Evidence of Statistical Support and Corroboration of Subgroup Claims in Randomized Clinical Trials.

Joshua D Wallach1, Patrick G Sullivan2, John F Trepanowski3, Kristin L Sainani4, Ewout W Steyerberg5, John P A Ioannidis6.   

Abstract

Importance: Many published randomized clinical trials (RCTs) make claims for subgroup differences. Objective: To evaluate how often subgroup claims reported in the abstracts of RCTs are actually supported by statistical evidence (P < .05 from an interaction test) and corroborated by subsequent RCTs and meta-analyses. Data Sources: This meta-epidemiological survey examines data sets of trials with at least 1 subgroup claim, including Subgroup Analysis of Trials Is Rarely Easy (SATIRE) articles and Discontinuation of Randomized Trials (DISCO) articles. We used Scopus (updated July 2016) to search for English-language articles citing each of the eligible index articles with at least 1 subgroup finding in the abstract. Study Selection: Articles with a subgroup claim in the abstract with or without evidence of statistical heterogeneity (P < .05 from an interaction test) in the text and articles attempting to corroborate the subgroup findings. Data Extraction and Synthesis: Study characteristics of trials with at least 1 subgroup claim in the abstract were recorded. Two reviewers extracted the data necessary to calculate subgroup-level effect sizes, standard errors, and the P values for interaction. For individual RCTs and meta-analyses that attempted to corroborate the subgroup findings from the index articles, trial characteristics were extracted. Cochran Q test was used to reevaluate heterogeneity with the data from all available trials. Main Outcomes and Measures: The number of subgroup claims in the abstracts of RCTs, the number of subgroup claims in the abstracts of RCTs with statistical support (subgroup findings), and the number of subgroup findings corroborated by subsequent RCTs and meta-analyses.
Results: Sixty-four eligible RCTs made a total of 117 subgroup claims in their abstracts. Of these 117 claims, only 46 (39.3%) in 33 articles had evidence of statistically significant heterogeneity from a test for interaction. In addition, out of these 46 subgroup findings, only 16 (34.8%) ensured balance between randomization groups within the subgroups (eg, through stratified randomization), 13 (28.3%) entailed a prespecified subgroup analysis, and 1 (2.2%) was adjusted for multiple testing. Only 5 (10.9%) of the 46 subgroup findings had at least 1 subsequent pure corroboration attempt by a meta-analysis or an RCT. In all 5 cases, the corroboration attempts found no evidence of a statistically significant subgroup effect. In addition, all effect sizes from meta-analyses were attenuated toward the null. Conclusions and Relevance: A minority of subgroup claims made in the abstracts of RCTs are supported by their own data (ie, a significant interaction effect). For those that have statistical support (P < .05 from an interaction test), most fail to meet other best practices for subgroup tests, including prespecification, stratified randomization, and adjustment for multiple testing. Attempts to corroborate statistically significant subgroup differences are rare; when done, the initially observed subgroup differences are not reproduced.

Entities:  

Mesh:

Year:  2017        PMID: 28192563      PMCID: PMC6657347          DOI: 10.1001/jamainternmed.2016.9125

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


  32 in total

Review 1.  Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects.

Authors:  David M Kent; Ewout Steyerberg; David van Klaveren
Journal:  BMJ       Date:  2018-12-10

2.  Fakery and science.

Authors:  Saul Miller
Journal:  Br J Gen Pract       Date:  2017-04       Impact factor: 5.386

3.  Exploring app features with outcomes in mHealth studies involving chronic respiratory diseases, diabetes, and hypertension: a targeted exploration of the literature.

Authors:  Sara Belle Donevant; Robin Dawson Estrada; Joan Marie Culley; Brian Habing; Swann Arp Adams
Journal:  J Am Med Inform Assoc       Date:  2018-10-01       Impact factor: 4.497

4.  Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death.

Authors:  Susanna F Fustolo-Gunnink; Karin Fijnvandraat; David van Klaveren; Simon J Stanworth; Anna Curley; Wes Onland; Ewout W Steyerberg; Ellen de Kort; Esther J d'Haens; Christian V Hulzebos; Elise J Huisman; Willem P de Boode; Enrico Lopriore; Johanna G van der Bom
Journal:  Blood       Date:  2019-12-26       Impact factor: 22.113

5.  Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis.

Authors:  Anthony J Comerota; Clive Kearon; Chu-Shu Gu; Jim A Julian; Samuel Z Goldhaber; Susan R Kahn; Michael R Jaff; Mahmood K Razavi; Andrei L Kindzelski; Riyaz Bashir; Parag Patel; Mel Sharafuddin; Michael J Sichlau; Wael E Saad; Zakaria Assi; Lawrence V Hofmann; Margaret Kennedy; Suresh Vedantham
Journal:  Circulation       Date:  2019-02-26       Impact factor: 29.690

6.  Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses.

Authors:  Stefan Schandelmaier; Matthias Briel; Ravi Varadhan; Christopher H Schmid; Niveditha Devasenapathy; Rodney A Hayward; Joel Gagnier; Michael Borenstein; Geert J M G van der Heijden; Issa J Dahabreh; Xin Sun; Willi Sauerbrei; Michael Walsh; John P A Ioannidis; Lehana Thabane; Gordon H Guyatt
Journal:  CMAJ       Date:  2020-08-10       Impact factor: 8.262

Review 7.  Does evidence support the high expectations placed in precision medicine? A bibliographic review.

Authors:  Jordi Cortés; José Antonio González; María Nuncia Medina; Markus Vogler; Marta Vilaró; Matt Elmore; Stephen John Senn; Michael Campbell; Erik Cobo
Journal:  F1000Res       Date:  2018-01-09

8.  Safety and efficacy of probiotic administration to preterm infants: ten common questions.

Authors:  Mark A Underwood; Erin Umberger; Ravi M Patel
Journal:  Pediatr Res       Date:  2020-08       Impact factor: 3.756

9.  Models with interactions overestimated heterogeneity of treatment effects and were prone to treatment mistargeting.

Authors:  David van Klaveren; Theodor A Balan; Ewout W Steyerberg; David M Kent
Journal:  J Clin Epidemiol       Date:  2019-06-10       Impact factor: 6.437

10.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration.

Authors:  David M Kent; David van Klaveren; Jessica K Paulus; Ralph D'Agostino; Steve Goodman; Rodney Hayward; John P A Ioannidis; Bray Patrick-Lake; Sally Morton; Michael Pencina; Gowri Raman; Joseph S Ross; Harry P Selker; Ravi Varadhan; Andrew Vickers; John B Wong; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2019-11-12       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.